Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer

European Journal of Endocrinology

Volumn 173, Issue 1, 2015, Pages 29-36

  Vannucchi, Guia ^a   De Leo, Simone ^b   Perrino, Michela ^b   Rossi, Stefania ^c   Tosi, Delfina ^d   Cirello, Valentina ^b   Colombo, Carla ^b   Bulfamante, Gaetano ^c,d   Vicentini, Leonardo ^a   Fugazzola, Laura ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAN PAOLO HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; THYROGLOBULIN; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCAL METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PAPILLARY THYROID CANCER; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR CONVERSION PHENOMENON; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TUMOR CLASSIFICATION; TUMOR VOLUME; BIOSYNTHESIS; CARCINOMA, PAPILLARY; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; ONSET AGE; PATHOLOGY; THYROID NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREVALENCE; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, PROGESTERONE; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84930639293     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-0054     Document Type: Article

References (36)

1. Franceschi S & Wild CP. Meeting the global demands of epidemiologic transition - the indispensable role of cancer prevention. Molecular Oncology 2013 7 1-13. (doi:10.1016/j.molonc.2012.10.010)
2. Manole D, Schildknecht B, Gosnell B, Adams E & Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. Journal of Clinical Endocrinology and Metabolism 2001 86 1072-1077.
3. Zeng Q, Chen G, Vlantis A, Tse G & van Hasselt C. The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. Journal of Pathology 2008 214 425-433. (doi:10.1002/path.2297)
4. Dong W, Zhang H, Li J, Guan H, He L, Wang Z, Shan Z & Teng W. Estrogen induces metastatic potential of papillary thyroid cancer cells through estrogen receptor α and β. International Journal of Endocrinology 2013 2013 941568. (doi:10.1155/2013/941568)
5. Zeng Q, Chen GG, Vlantis AC & van Hasselt CA. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Proliferation 2007 40 921-935. (doi:10.1111/j.1365-2184.2007.00471.x)
6. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Andò S & Maggiolini M. 17β-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. Molecular Pharmacology 2006 70 1414-1423. (doi:10.1124/mol.106.026344)
7. Kumar A, Klinge CM & Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors α and β. International Journal of Oncology 2010 36 1067-1080. (doi:10.3892/ijo-00000629)
8. Santin AP & Furlanetto TW. Role of estrogen in thyroid function and growth regulation. Journal of Thyroid Research 2011 2011 875125. (doi:10.4061/2011/875125)
9. Di Vito M, De Santis E, Perrone GA, Mari E, Giordano MC, De Antoni E, Coppola L, Fadda G, Tafani M, Carpi A et al. Overexpression of estrogen receptor-a in human papillary thyroid carcinomas studied by laser-capture microdissection and molecular biology. Cancer Science 2011 102 1921-1927. (doi:10.1111/j.1349-7006.2011.02017.x)
10. Chen GG, Vlantis AC, Zeng Q & van Hasselt CA. Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Current Cancer Drug Targets 2008 8 367-377. (doi:10.2174/156800908785133150)
11. Xhaard C, Rubino C, Cléro E, Maillard S, Ren Y, Borson-Chazot F, Sassolas G, Schvartz C, Colonna M, Lacour B et al. Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in young women in France: a population-based case-control study. American Journal of Epidemiology 2014 180 1007-1017. (doi:10.1093/aje/kwu220)
12. Vannucchi G, Perrino M, Rossi S, Colombo C, Vicentini L, Dazzi D, Beck-Peccoz P & Fugazzola L. Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. European Journal of Endocrinology/European Federation of Endocrine Societies 2010 162 145-151. (doi:10.1530/EJE-09-0761)
13. Messuti I, Corvisieri S, Bardesono F, Rapa I, Giorcelli J, Pellerito R, Volante M & Orlandi F. Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features. European Journal of Endocrinology/European Federation of Endocrine Societies 2014 170 659-666. (doi:10.1530/EJE-13-0903)
14. Shindo H, Amino N, Ito Y, Kihara M, Kobayashi K, Miya A, Hirokawa M & Miyauchi A. Papillary thyroid microcarcinoma might progress during pregnancy. Thyroid 2014 24 840-844. (doi:10.1089/thy.2013.0527)
15. Ron E, Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT &Fraumeni JF Jr. A population-based case-control study of thyroid cancer. Journal of the National Cancer Institute 1987 79 1-12.
16. Zahid M, Beseler CL, Hall JB, LeVan T, Cavalieri EL & Rogan EG. Unbalanced estrogen metabolism in ovarian cancer. International Journal of Cancer 2014 134 2414-2423. (doi:10.1002/ijc.28565)
17. Magri F, Capelli V, Rotondi M, Leporati P, La Manna L, Ruggiero R, Malovini A, Bellazzi R, Villani L & Chiovato L. Expression of estrogen and androgen receptors in differentiated thyroid cancer: an additional criterion to assess the patient's risk. Endocrine-Related Cancer 2012 19 463-471. (doi:10.1530/ERC-11-0389)
18. Magri F, Capelli V, Gaiti M, Villani L, Zerbini F, La Manna L, Rotondi M & Chiovato L. ER-a and ER-b expression in differentiated thyroid cancer: relation with tumor phenotype across the TNM staging and peri-tumor inflammation. Endocrine 2015. In press. (doi:10.1007/s12020-014-0457-x)
19. Kansakar E, Chang YJ, Mehrabi M & Mittal V. Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer. American Surgeon 2009 75 785-789 discussion 789.
20. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds). American Joint Committee on Cancer 2012 TNM classification of malignant tumours. In AJCC Cancer Staging Handbook, 7th edn. New York: Springer Verlag.
21. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 1167-1214. (doi:10.1089/thy.2009.0110)
22. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W &European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology/European Federation of Endocrine Societies 2006 154 787-803. (doi:10.1530/eje.1.02158)
23. Perrino M, Vannucchi G, Vicentini L, Cantoni G, Dazzi D, Colombo C, Rodari M, Chiti A, Beck-Peccoz P & Fugazzola L. Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers < or =2 cm.Endocrine-Related Cancer 2009 16 201-210. (doi:10.1677/ERC-08-0119)
24. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L & Beck-Peccoz P. BRAF mutations in an Italian cohort of thyroid cancers. Clinical Endocrinology 2004 61 239-243. (doi:10.1111/j.1365-2265.2004.02089.x)
25. Vaiman M, Olevson Y, Sandbank J, Habler L, Zehavi S & Kessler A. Are estrogen receptors a detectable in normal and abnormal thyroid tissue? European Archives of Oto-Rhino-Laryngology 2010 267 1753-1757. (doi:10.1007/s00405-010-1269-0)
26. Vaiman M, Olevson Y, Habler L, Eviatar E, Zehari S, Sandbank J &Kessler A. The estrogen receptors in the papillary carcinoma of the thyroid gland. Oncology Research 2010 18 537-540. (doi:10.3727/096504010X12767359113802)
27. Yane K, Kitahori Y, Konishi N, Okaichi K, Ohnishi T, Miyahara H, Matsunaga T, Lin JC & Hiasa Y. Expression of the estrogen receptor in human thyroid neoplasms. Cancer Letters 1994 84 59-66. (doi:10.1016/0304-3835(94)90358-1)
28. Tavangar SM, Monajemzadeh M, Larijani B & Haghpanah V. Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. Singapore Medical Journal 2007 48 744-747.
29. Holdaway IM & Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983 52 479-485. (doi:10.1002/1097-0142(19830801)52:3〈479::AID-CNCR2820520317〉3.0.CO;2-O)
30. Amir E, Ooi WS, Simmons C, Kahn H, Christakis M, Popovic S, Kalina M, Chesney A, Singh G & Clemons M. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. Clinical Oncology 2008 20 763-768. (doi:10.1016/j.clon.2008.08.005)
31. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Research 2010 12 R75. (doi:10.1186/bcr2645)
32. Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP & Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Research 1997 57 1597-1604.
33. Hoefnagel LD, Moelans CB, Meijer SL, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID et al. Prognostic value of estrogen receptor a and progesterone receptor conversion in distant breast cancer metastases. Cancer 2012 118 4929-4935. (doi:10.1002/cncr.27518)
34. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocrine-Related Cancer 2006 13 455-464. (doi:10.1677/erc.1.01086)
35. Derwahl M & Nicula D. Estrogen and its role in thyroid cancer. Endocrine-Related Cancer 2014 21 T273-T283. (doi:10.1530/ERC-14-0053)
36. Moravej A, Jeddi-Tehrani M, Salek-Moghaddam AR, Dokouhaki P, Ghods R, Rabbani H, Kazemi-Sefat GE, Shahbazi M & Zarnani AH. Evaluation of thyroglobulin expression in murine reproductive organs during pregnancy. American Journal of Reproductive Immunology 2010 64 97-103. (doi:10.1111/j.1600-0897.2010.00827.x)